ALK-Abelló Earnings Call Signals Profitable Growth

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q4 earnings call. Read on for the main highlights of the call.

ALK‑Abelló’s latest earnings call struck an upbeat tone, underscoring a year of robust double‑digit growth, sharply higher profitability, and a marked turnaround in cash generation. Management balanced this optimism with a candid discussion of mix‑driven margin headwinds in 2026, rising pricing pressures in Europe, and execution risks around its expanding allergy pipeline.

Strong Top-Line Growth

ALK reported 2025 revenue of DKK 6.3 billion, up 15% in local currencies and roughly equivalent to USD 1 billion. Fourth‑quarter sales rose 17% year over year, powered by broad‑based demand across regions and a strong contribution from tablet therapies and anaphylaxis products.

Material Profitability Improvement

EBIT surged 53% for the full year to DKK 1.65 billion, lifting the EBIT margin to 26%, six points higher than a year ago and above the firm’s long‑standing 25% target. In Q4, EBIT jumped 88% and the margin reached 22%, reflecting tight cost control and scale benefits as volumes expanded.

Tablet Business Momentum

Tablet sales rose 17% for the year, with Europe up 19%, cementing tablets as the key growth engine in allergy immunotherapy. New pediatric launches of ACARIZAX and ITULAZAX drove a strong inflow of new patients, with tablet treatment initiations advancing well above 10% during 2025.

Patient Base Expansion

ALK estimates it treated about 500,000 additional patients in 2025, taking its global treated population to roughly 3.1 million. Around 300,000 of these incremental patients came from tablets, underpinning management’s confidence in the medium‑term growth outlook for its core immunotherapy franchise.

Strong Anaphylaxis Performance and neffy Traction

Sales of anaphylaxis and other products climbed 34% in 2025, with anaphylaxis alone up about 58%, reflecting growing demand for emergency treatments. In Germany, neffy captured an 18% value share and roughly 11–12% volume share by year‑end, and the product is now launching or progressing in the U.K., Greece, Denmark and Slovenia.

Improved Gross Margin and Cash Generation

Gross profit rose to DKK 4.2 billion, lifting the gross margin to 67%, three percentage points higher than in 2024, thanks to mix and efficiency gains. Free cash flow swung to a positive DKK 1.4 billion from a negative DKK 204 million, helped in part by a DKK 244 million upfront payment from partner GenSci.

Pipeline and R&D Progress

ALK advanced its innovation agenda with the start of a Phase II study for its peanut sublingual tablet, which has secured Fast Track status from the U.S. FDA and is expected to deliver topline data in Q2 2026. The company also flagged early work on biologic candidate ALK‑014, now in preclinical development and potentially ready for first‑in‑human trials in the next one to two years.

Strategic Partnerships and Market Access Wins

Management highlighted progress with partners GenSci in China, Shionogi and Torii in Japan, and ARS Pharma in the U.S., which together extend the reach of ALK’s portfolio and neffy co‑promotion. On market access, ACARIZAX has now been approved for children in 30 countries and launched in 21, while ITULAZAX is approved for younger patients in 20 countries and launched in 13.

Expected Gross Margin Mix Headwind in 2026

Looking ahead, ALK expects its gross margin to slip slightly in 2026 as partner‑driven sales in China and Japan and rising neffy volumes, which carry lower margins, gain weight in the mix. Ongoing production efficiencies should partly offset this pressure, but management signaled investors should not extrapolate 2025’s 67% margin higher.

neffy Adoption and Market-Shaping Challenges

Despite early share gains, management stressed that neffy faces an entrenched standard of care in anaphylaxis that will take time and sustained effort to shift. They framed 2026 as a buildup year, with a focus on physician education, access work and market‑shaping rather than expecting explosive near‑term revenue from the product.

Pricing and Rebate Risks in Europe

ALK acknowledged that price reductions and changing rebate structures, particularly in France and potentially Germany, represent a tangible drag on growth and profitability. These pressures have been baked into the lower end of 2026 guidance, signaling a conservative stance on European pricing dynamics.

Management Change in R&D

The departure of Head of R&D Henriette Mersebach by mutual agreement introduces uncertainty just as ALK approaches a pivotal Phase II readout in peanut allergy. An interim special adviser is supporting the R&D function while the company searches for a new leader, a transition investors will watch closely given its growing pipeline.

Japan and Supply/Phasing Constraints

In Japan, revenue was held back by shipment timing and partner capacity constraints at Torii and Shionogi, limiting the ability to fully meet demand for CEDARCURE tablets. A new production facility has now come online, and management expects this to ease bottlenecks and improve supply reliability going forward.

SCIT Volume Pressure from Tablet Conversion

Traditional SCIT allergy treatments saw muted patient initiations in core markets, as some patients shifted to tablets, restraining SCIT sales growth. Combined SCIT and SLIT products grew a modest 3% in the quarter and around 5% for the year, underscoring how tablets are reshaping the company’s therapy mix.

Dependence on Partner Payments and One-Off Effects

The cash flow inflection was not purely operational, with the GenSci upfront payment and prior‑year items such as a large ARS license fee and acquisition costs influencing comparisons. Management implicitly cautioned that investors should normalize for these one‑offs when assessing the sustainability of the free cash flow run‑rate.

Short-Term Quarterly Volatility Risk

ALK flagged that the timing of shipments to China and Japan, as well as market access milestones such as formulary listings in the U.K. or provincial rollouts in Canada, could cause uneven quarterly numbers. While the full‑year trajectory is expected to remain positive, shareholders should brace for some seasonality and phasing‑driven volatility.

Guidance and Forward-Looking Outlook

For 2026, ALK is guiding for 11–15% organic revenue growth in local currencies, anchored by double‑digit gains in tablets and anaphylaxis and low single‑digit growth in SCIT and SLIT drops. The company aims to keep the EBIT margin around 25%, with slightly lower gross margins, rising R&D and sales investments, free cash flow of DKK 800–1,000 million and CapEx near DKK 500 million.

ALK’s earnings call painted a picture of a business shifting from turnaround to disciplined growth, with tablets and anaphylaxis emerging as powerful profit drivers. While investors must weigh mix‑driven margin pressure, European pricing risks and execution around pipeline and partnerships, the core message was one of solid momentum and confidence in sustaining attractive mid‑teens growth.